An interventional study of Bloat Gummies and Placebo in Digestive Health, Abdominal Discomfort and Gas and Bloating, sponsored by Arrae. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Arrae · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Mucopolysaccharidosis IV with a site in United States — 16 open to participants now, 18 under way, 1 of them phase 3. Mucopolysaccharidosis IV · United States.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, this one is the 11th largest by planned enrollment of the 30 interventional ones that give a count, is one of 4 that started in 2026, is one of 9 with no phase, reaches primary completion later than 0 of the 17 other live ones, and was the 55th registered.
101 studies on the registry are indexed under Mucopolysaccharidosis IV; 27 are open to participants now.
Browse Mucopolysaccharidosis IV studies →16 of the 56 studies in Mucopolysaccharidosis IV with a site in United States are open now. Recruiting first, the newest first:
Kiwi Health Inc · Sites in United States
Ages 18+ · Healthy volunteers
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 4 more countries
Ages 0 yrs–32 mo
Children's Hospital of Orange County · Sites in United States
Ages 0–99 · Healthy volunteers
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Sites in United States
Ages 2–100
QED Therapeutics, a BridgeBio company · Sites in United States, Australia, Canada and 7 more countries
Ages 30 mo–16 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Mucopolysaccharidosis IV studies recruiting now, 9 (45%) set no upper age limit and 7 (35%) stop at 75 or younger; 15 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 12 · Phase 3 4 · Phase 4 3
First in 1998; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 61 across 56 interventional studies indexed under Mucopolysaccharidosis IV.
Median enrollment 88 across the 30 interventional studies, 131 across the 25 observational. Of the 36 that completed or were terminated, 10 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 56 have an industry lead sponsor. The 10 most frequent:
Arrae is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Arrae has 1 study filed under Mucopolysaccharidosis IV — fewer than ten, so there is no comparison to draw.
5 of the studies in Mucopolysaccharidosis IV with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06873035Phase 3QED Therapeutics, a BridgeBio companyAn Interventional Study of Infigratinib in Children With Hypochondroplasia | 2027-01 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT04152551Hospital for Special Surgery, New YorkEffects of Bisphosphonates on OI-Related Hearing Loss | 2027-01 |
| NCT05284006Nemours Children's ClinicNon-invasive Functional Assessment and Pathogenesis of Morquio A | 2027-04-30 |
| NCT05031507Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Study of Skeletal Disorders | 2027-07-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 56 studies in Mucopolysaccharidosis IV with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this crossover clinical trial is to evaluate the efficacy and safety of Bloat Gummies on postprandial bloating and related gastrointestinal discomfort in healthy adults with recurrent bloating. The main question it aims to answer is whether Bloat gummies reduce post-meal bloating, gas, or abdominal pain (stomach) discomfort. Participants will be asked to consume one dose of Bloat or Placebo after 2 test meals and answer questionnaires on gas, bloating and abdominal distension.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bloat is a gummy that contains the active ingredients ginger root extract, lemon balm extract, dandelion root extract and the postbiotic HTES1, Bifidobacterium longum CECT7347.
Dietary Supplement: Bloat Gummies
The placebo is a gummy that looks and tastes like the study gummy, but with no active ingredients.
Dietary Supplement: Placebo
Participants will be instructed to take one dose (2 gummies) 30 minutes after consumption of the entire standardized meal during 2 test meal sessions, at least 7 days apart.
Participants will be instructed to take one dose (2 gummies) 30 minutes after consumption of the entire standardized meal during 2 test meal sessions, at least 7 days apart.
Mean change in bloating severity from pre-dose to t = 60 minutes post-dose as, comparing active product vs. placebo.
Bloating severity assessed by Bloating Likert Scale of 0 to 4, with 0 being "no symptoms" and 4 being "severe symptoms."
Time frame: Evaluated from pre-dose to 60 minutes post-dose
Mean change in bloating severity from pre-dose to t = 30 minutes post-dose, comparing active product vs placebo.
Bloating severity assessed by Bloating Likert Scale of 0 to 4, with 0 being "no symptoms" and 4 being "severe symptoms."
Time frame: Evaluated from pre-dose to 30 minutes post-dose
Mean change in gas severity from pre-dose to t = 30 and 60 minutes post-dose, comparing active product vs. placebo.
Gas severity will be assessed by a Gas Likert scale of 0 to 4, with 0 being "no symptoms" and 4 being "severe symptoms."
Time frame: Evaluated from pre-dose to 30 and 60 minutes post-dose.
Mean change in abdominal discomfort severity from pre-dose to t = 30 and 60 minutes post-dose, comparing active product vs. placebo.
Abdominal discomfort assessed by abdominal discomfort Likert Scale, of 0 to 4, with 0 being "no symptoms" and 4 being "severe symptoms."
Time frame: Evaluated from pre-dose to 30 and 60 minutes post-dose.
Mean change in waist circumference from pre-dose to t = 30 and t = 60 minutes post-dose, comparing active product vs. placebo.
Abdominal distension assessed by mean change in waist circumference measurement.
Time frame: Evaluated from pre-dose to 30 and 60 minutes post-dose.
Proportion of participants demonstrating a reduction in waist circumference.
Abdominal distension assessed by mean change in waist circumference measurement.
Time frame: Evaluated at 30 minutes, 60 minutes or both timepoints post-dose.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Apr 2026; primary completion for Jun 2026, 2 months later.
Of 19 interventional studies with no phase under Mucopolysaccharidosis IV, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 2 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arrae